Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells
Author
Other authors
Publication date
2017-02Abstract
A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
Document Type
Article
Published version
Language
English
Subject (CDU)
616 - Pathology. Clinical medicine
Keywords
Fotoquimioteràpia
Duxorubicina
Fotosensibilització (Biologia)
Photodynamic therapy
Doxorubicin
Pheophorbide a
Synergic treatment
HeLa cells
Pages
18 p.
Publisher
MDPI
Is part of
Cancers. Vol.9, n.2 (2017), 18
Grant agreement number
info:eu-repo/grantAgreement/MINECO/PN I+D/CTQ2013-48767-C3-1-R
info:eu-repo/grantAgreement/MINECO/PN I+D/CTQ2013-48767-C3-3-R
info:eu-repo/grantAgreement/URL i La Caixa/Projectes recerca PDI/2016-URL-Trac-013
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2016 FI_B1 00021
This item appears in the following Collection(s)
Rights
© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/